Compare Pfizer Inc (PFE) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Wheaton Precious Metals Corp — how do they compare? Pfizer Inc trades at $27.83 (market cap $158.56B), while Wheaton Precious Metals Corp trades at $137.95 (market cap $61.17B). The key difference: Pfizer Inc is far larger — about 2.6× Wheaton Precious Metals Corp's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Wheaton Precious Metals Corp for 66 Days on average.
| PFE | WPM | |
|---|---|---|
Market Cap | $158.56B | $61.17B |
Volume | 44,138,282 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $29.02 | $165.72 |
52-Week Low | $23.67 | $94.37 |
Typical Hold Time | 158 Days | 66 Days |
Enterprise Value | $210.06B | $63.05B |
Dividend Yield | 6.18% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% today, amid a bearish technical signal. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, driven by high margins and consistent earnings beats. Recent news highlights expansion plans targeting 1.2M ounces by 2030, supported by a robust deal pipeline. Analyst consensus remains strongly bullish with an 80% buy rating and a $164.80 price target, suggesting significant upside from current levels despite near-term technical weakness.
The outlook for WPM is positive due to strong earnings growth, high profitability, and strategic streaming acquisitions. Risks include exposure to gold/silver price volatility, execution of growth targets, and macroeconomic factors like interest rates. With solid cash flow and institutional support, the stock presents a compelling long-term opportunity, though investors should monitor commodity cycles and operational milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
